Cipla receives EIR from USFDA for Indore plant; Stock rises

23 Sep 2022 , 11:32 AM

Cipla Limited stocks in focus after the announcement of  closure of US FDA product-specific Pre-Approval Inspection.

As per the regulatory filing, following the product specific Pre-Approval Inspection (PAI) by the United States Food and Drug Administration (USFDA) at the Indore plant from June 27, 2022 to July 01, 2022, the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection, it said on Thursday.

On Friday, at around 11:33 AM, Cipla Ltd is currently trading at Rs1,068.90 per share up by Rs7.2 or 0.68% from its previous closing of Rs1,061.70 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]